The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy

FAR-TNM predicts the survival in gastric cancer patients after gastrectomy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046849

Enrollment

Unknown

Registered

2021-05-29

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Observation group:?

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All patients with GC underwent a total or subtotal gastrectomy with standard lymphadenectomy; 2. With available preoperative serum data of Fibrinogen and Albumin; 3. With adequate clinicopathological data and overall survival (OS) data.

Exclusion criteria

Exclusion criteria: 1. Prior pre-operation anticancer treatment, such as radiochemotherapy; 2. Acute inflammatory disease, autoimmune disease, chronic renal failure, liver cirrhosis, or haematopoietic system disease.

Design outcomes

Primary

Measure	Time frame
Fibrinogen level;Albumin;	—

Countries

China

Contacts

Public ContactZhang Xunlei

Nantong Tumor Hospital

477750911@qq.com+86 15716288726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026